Path to FDA Approval

HEATT

  • A Final Report for the Phase I Lung Cancer trial was filed – Ann Thorac Surg. 2004; 77(6):1916

  • A Final Report for the Phase I Ovarian Cancer trial is expected to be submitted to the FDA in the 3rd Quarter of 2020

  • With FDA approval, Verthermia is ready to begin treatments within 60-90 days.

Verthermia Acquisitions Inc.

HEATT  

1887 Whitney Mesa Dr., #1981 Henderson, NV 89014

info@verthermia.com  |   Tel: 917.985.3400

©2020 Verthermia Aquisitions Inc. All Rights Reserved.

  • Twitter
  • Facebook
  • LinkedIn
  • Instagram

®